Study limitations include the need for additional models of AR-driven prostate cancer.<h4>Conclusions and clinical implications</h4>The emergence of ARv567es via gene rearrangements causes transcriptional reprogramming and therapy resistance. This evidence concerns the gene AR and prostate carcinoma.